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Immune reconstitution inflammatory syndrome (IRIS) refers 
to an ‘unexpected’ and paradoxical clinical deterioration in 
the period immediately after initiation of antiretroviral 
therapy (ART). Diagnosis of IRIS relates to the time frame 
after initiation of antiretroviral therapy ART, response to 
ART and exclusion of alternative diagnoses. Boulware et 
al. proposed criteria for children.1 There are fewer data on 
incidence, prevalence and clinical descriptions in infants 
and children than in adults. Studies report a prevalence 
of up to 21% in South African infants.2 IRIS is commonly 
associated with mycobacterial infections, mainly bacille 
Calmette-Guérin (BCG), Mycobacterium tuberculosis and 
non-tuberculous mycobacteria (NTM).2-5 Other condi-
tions such as skin disease, herpes simplex, cryptococcal 
meningitis and immune diseases such as Guillain-Barré 
syndrome are also reported.1,3 Age and geographical lo-
cation are important determinants of the risk for each 
disease. Table I summarises the most pertinent paediatric 
literature. 
M. TUBERCULOSIS IRIS
EPIDEMIOLOGICAL CONSIDERATIONS IN HIV-
INFECTED CHILDREN
Tuberculosis (TB) is a common opportunistic infection in 
HIV-infected African children. Rates of 53.3 cases/100 pa-
tient-years are reported in children not on highly active 
antiretroviral therapy (HAART).6 High rates of exposure to 
potentially infectious source cases are well documented 
in HIV-exposed infants7 and rates of disease of 1 596 
cases per 100 000 HIV-infected infants are documented 
in Cape Town.8 Young age and HIV-related immunosup-
pression contribute to this high disease burden.
Recurrent episodes of TB are well documented and are 
caused by both relapse and re-infection.9 In a cohort 
studied before and after widespread availability of ART, 
30% of children with HIV and culture-confirmed TB had 
received prior TB therapy.6
Rates of drug-resistant TB vary between settings. Drug 
resistance was reported in 17% of HIV-infected children 
with TB, 6.8% having resistance to both rifampicin and 
isoniazid.10 Children with prior TB therapy are at higher 
risk of resistance.11 There may be an incomplete thera-
peutic response to 6 months of standard anti-TB ther-
apy.9 
Up to a third of children initiating HAART may be on 
anti-TB therapy.6,12 Cohort data from low-resource set-
tings indicate that the majority of children still initiate 
HAART at very low CD4 counts and with significant clini-
cal disease.13 These children are at high risk for IRIS and 
incident TB from new exposure to M. tuberculosis. With 
improved access to HAART, an up to 70% reduction in 
the incident TB can be achieved.6,14
DIAGNOSTIC CONSIDERATIONS
The diagnosis of TB in HIV-infected children remains dif-
ficult. Signs and symptoms overlap with advanced HIV. 
Clinical scoring tools have poor specificity in HIV-infect-
ed children.15,16   
Sputum is difficult to collect in young children, and gas-
tric washings are frequently not performed.17 Culture 
yields from gastric washings and induced sputa are low 
in children. Although yields of up to 40%18 have been re-
ported in research settings, the yield in clinical settings is 
IMMUNE RECONSTITUTION 
INFLAMMATORY SYNDROME IN CHILDREN
CL IN ICAL
Helena Rabie1, FCP (Paed)
Tammy Meyers2, FCP (Paed)
Mark F Cotton1, PhD
1Department of Paediatrics and Child Health, Tygerberg Children’s Hospital and Stellenbosch University, Tygerberg, W Cape
2Harriet Shezi Paediatric ARV Clinic, Chris Hani Baragwanath Hospital, Johannesburg
Paradoxical deterioration due to immune reconstitution inflammatory syndrome (IRIS) occurs in up to 21% of 
children initiating antiretroviral therapy. Mycobacterial diseases are the most common, with BCG-vaccine adenitis 
predominating in infants and Mycobacterium tuberculosis (TB) in older children. The difficulty of diagnosing TB in 
HIV-infected children and the increasing risk of drug-resistant TB complicate the diagnosis and management of 
both paradoxical IRIS and post-antiretroviral therapy TB. History and clinical assessment remain key strategies in 
the management of these infants and children. There are no prospective studies investigating diagnostic criteria 
and therapeutic strategies in children.
T H E  S O U T H E R N  A F R I C A N  J O U R NA L  O F  H I V  M E D I C I N E                             D E C EMB E R  2 0 0 9 71
lower.19 In children with a high index of suspicion for TB, 
microbiological confirmation can be obtained in 55%, 
increasing to 80% with significant pulmonary infiltra-
tion.16 Chest radiographs are difficult to interpret owing 
to ubiquitous chronic underlying HIV-associated lung 
disease. Tuberculin skin tests have a reduced sensitiv-
ity despite adjusting the extent of induration from 10 
mm to 5 mm.20 The value of interferon-gamma release 
assays in HIV-infected children is still under study. Nega-
tive results do not exclude TB,21 and tests are expensive. 
Although failure of therapy for an opportunistic infec-
tion is considered an exclusion criterion for IRIS, IRIS 
has been diagnosed in adults with inadequately treated 
drug-resistant TB.22 As the diagnosis of TB is seldom con-
firmed by culture and drug sensitivity is often not avail-
able, it may be difficult to differentiate IRIS from poor 
response to treatment and drug resistance. It may not be 
possible to confirm a response to HAART because of lack 
of access to virological testing. If events occur soon after 
initiation of therapy, significant reductions in viral load 
and clinical responses may not yet have occurred. 
THERAPEUTIC CONSIDERATIONS
Current dosages of anti-TB medicines, especially isoni-
azid and rifampicin, are insufficient in all children; this 
is probably exacerbated in children with HIV, in whom 
malabsorption is common.23-25 
Rifampicin reduces exposure to protease inhibitors (PIs) 
and non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), thereby compromising HAART efficacy. Riton-
avir-based HAART, previously recommended for co-
treated children on PIs, has been associated with poorer 
virological outcomes.26 
POST-HAART TB AND UNMASKING IRIS
Besides the general principles proposed by Boulware,1 
there are no proposed criteria to distinguish true IRIS 
from incident TB or missed disease prior to HAART 
initiation. Adult clinicians have suggested that all 
cases of TB after initiation of HAART should be termed 
post-HAART TB, with only cases occurring in the first 
3 months accompanied by heightened clinical features 
classified as IRIS.27 Data from cohort studies report TB 
rates of 3.4 - 6.2% in African children after initiating 
HAART6,28 (Table I). In infants TB-IRIS is thought to be 
less common than BCG-IRIS.2 Clustering of these cases 
in the first 100 days after HAART initiation is reported 
from cohort studies. In a large Ugandan study, a 2.7-
fold increase in risk for TB was observed early after the 
initiation of HAART.28 This could be due to inadequate 
screening procedures, as the converse was noted in a 
study where active screening was done.6
Few studies provide detailed assessment of the severity 
of disease, an essential component in distinguishing 
between IRIS, incident TB and disease missed prior to 
initiating HAART. Zampoli et al. described 7 children with 
post-HAART pulmonary TB IRIS, and 1 with additional 
extrapulmonary disease.29 Three (43%) had received 
therapy prior to the initiation of HAART. Culture was 
positive in 4 of the 7 cases. Of these, 1 had multidrug 
resistance, having stopped anti-TB therapy 3 weeks 
before initiating HAART. All chest radiographs showed 
significant adenopathy with airways compression, 
extensive parenchymal infiltration and pleural 
reactions.29 Although all IRIS is associated with significant 
inflammatory response, radiological findings are similar 
in HIV-infected children not on HAART.10 Clinicians 
therefore need to judge the relative severity of these 
conditions. Exposure to M. tuberculosis shortly after 
initiation of HAART could conceivably present as post-
HAART TB IRIS.30 This is especially relevant in children 
immunologically primed by receiving BCG at birth.
IRIS caused by both BCG and TB in the same patient is 
now well documented in two prospective paediatric co-
horts. In the NEVEREST study 50% of children with TB 
also had BCG IRIS.2 In the CHER cohort, 19% of children 
with BCG IRIS adenitis also had TB IRIS.31
PARADOXICAL IRIS
Delaying the initiation of ART in TB cases with severe im-
munodeficiency is associated with increased HIV-related 
mortality.32 Currently the World Health Organization 
(WHO) recommends that children with severe immune 
suppression or stage 4 disease should initiate ART 2 - 8 
weeks after the initiation of anti-TB therapy.33 
The basic diagnostic criteria for IRIS1 should be met first 
when diagnosing paradoxical IRIS. The proposed case 
definitions for TB paradoxical IRIS, although appropriate 
for well-resourced settings, are problematic in lower-re-
source settings. This is due to the diagnostic uncertainty 
of TB in HIV-infected children and difficulty in excluding 
alternative diagnoses and confirming a response to ART 
because of inability to measure CD4 counts or viral load, 
especially in rural areas.  
Few data exist on the risk of paradoxical IRIS. The study 
from Uganda reports only 2 cases of paradoxical IRIS.27 
Zampoli et al. recently described the clinical events in 4 
children receiving anti-TB therapy for 21 - 59 days be-
fore initiation of ART, who subsequently developed TB 
IRIS between 6 and 105 days later. Skin test conversion 
was documented in 1 child and was positive at the time 
of exacerbation in another. Two children presented with 
deterioration of pulmonary TB, 1 developed local adeni-
tis and another abdominal adenitis. One child died.29 
There is little information on clinical features and man-
agement of neurological paradoxical IRIS in children. 
In adults these account for 12% of cases of paradoxi-
cal TB IRIS.34 Similarly, intra-abdominal TB IRIS is com-
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mon in adults, occur-
ring in 37% of cases.35 
Although paediatric 
cases do occur (Helena 
Rabie – unpublished 
data), little is known 
about the prevalence in 
children.
It is challenging to ex-
clude drug-resistant TB 
and failure of TB ther-
apy for other reasons 
in these children. Re-
sistance was common 
in an adult series from 
Cape Town.22 The case 
in Fig. 1 illustrates the 
diagnostic difficulties 
in a setting of paradox-




Contact with a source 
case has been docu-
mented in 30 - 54% 
of HIV-infected chil-
dren with TB.6,10 TB can 
therefore be prevented 
and detected through 
a careful history look-
ing for a source case 
in the household and 
extended social circle. 
In older children and 
adolescents transmis-
sion may occur outside 
the family due to social 
mobility, and it is likely 
that a history of con-
tact will be a less sen-
sitive marker to distin-
guish incident TB from 
IRIS.
Reviewing adherence 
to anti-TB therapy and 
ART is essential to eval-
uate children with sus-
pected paradoxical TB 
IRIS. Documentation of 
suspected contact with 
a source patient who 
may have drug-resist-






















































































































































































































































































































































































































































































































































































































































































































































T H E  S O U T H E R N  A F R I C A N  J O U R NA L  O F  H I V  M E D I C I N E                             D E C EMB E R  2 0 0 9 73
adults diagnosed with paradoxical TB IRIS, resistance is 
a major clinical confounder.22 Weight gain on therapy 
may be an important and measurable clinical marker 
supporting IRIS rather than clinical deterioration. This 
information, together with clustering in the first 100 
days, may allow for a possible differentiation between 
incident TB and IRIS in younger children. Culture for M. 
tuberculosis and drug sensitivity testing should be con-
ducted whenever possible. Clinical judgement should 
guide clinicians as to additional investigations needed 
to exclude additional diagnoses such as acute bacterial 
infections, drug reactions and other opportunistic infec-
tions or malignancies. 
MANAGEMENT
Children are at higher risk than adults of death and 
hospitalisation in the period immediately after HAART 
initiation. Mortality of 17.4/100 000 patient-years in the 
first 3 months of therapy has been reported. Up to 30% 
require hospitalisation in the first 6 months on thera-
py. Two-thirds of the admissions are related to bacte-
rial infection and pneumonia.36,37 Withholding antibiotic 
therapy and other interventions at initial presentation is 
therefore very dangerous when TB IRIS is suspected. 
As in adults, therapy for TB IRIS includes the anti-TB 
therapy and continuation of HAART. However, if the IRIS 
event is life-threatening or likely to cause permanent 
disability (i.e. TB meningitis with clinical deterioration), 
HAART may be discontinued temporarily. Children on 
PIs can stop all drugs simultaneously. There is a signifi-
cant risk for resistance when stopping efavirenz or ne-
virapine.38 Clinicians need to weigh the risk of inducing 
NNRTI resistance against that of continuing either NRTIs 
or boosted lopinavir/ritonavir for 7 - 14 days. The safety 
of these strategies is unknown in this scenario.
Steroids improve outcomes for adults with moderate to 
severe TB IRIS, but there are no randomised studies in 
children.39 As in adults, clinicians must weigh the risk 
of resistant TB prior to starting steroid therapy. Other 
modalities used (but not studied) include non-steroi-
dal anti-inflammatory drugs (NSAIDs), thalidomide and 
leucotriene receptor antagonists.40-44 Despite the lack of 
data, it is reasonable to stratify the use of supportive 
therapy as follows: NSAIDs for mild to moderate disease, 
and steroids for severe disease. In cases where there is 
a prior indication, i.e. meningitis, steroids should always 
be used.  It is unclear whether pre-emptive steroids or 
NSAIDs can prevent IRIS (a trial in adults is underway). 
BCG-RELATED IRIS
BCG is the most common mycobacterial IRIS in infants 
given BCG at birth.2 Vaccine site ulceration and abscess 
formation, ipsilateral adenitis and exacerbation of dis-
seminated disease occur.45 Where ART is delayed until 
clinically indicated, 6% of all children and 14% of in-
fants experience BCG-related adverse events. In this set-
ting, age at initiation is the most important risk factor.2,46 
When children access therapy early and at a younger 
age, a low CD4 count is the most important predictor.45 
Although there is a significant reduction in the risk of 
IRIS with early initiation of ART adverse events are com-
mon in these infants also.31
Fig. 1. Drug-resistant TB presenting as paradoxical IRIS in a 
12-year-old girl with pulmonary and abdominal TB and severe 
immune suppression (chest radiograph a). She was sputum 
smear positive and had a CD4 count of 31 cells/µl. Anti-TB 
therapy with four drugs was initiated and she responded 
well, smear conversion taking place within 3 weeks. ART was 
started 3 weeks after initiation of TB therapy, and 7 days later 
she developed a high fever, severe abdominal pain and food 
intolerance. The sputum smear was now positive, and a chest 
radiograph (b) suggested miliary TB. Steroids were added 
with some clinical improvement. Rifampicin resistance was 
confirmed after 48 days on TB therapy and 27 days on ART.
a
b
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The diagnosis of IRIS remains clinical. Where systemic 
disease is suspected, extensive investigation may be re-
quired. Although no prospective studies have been con-
ducted, it is likely that local and regional IRIS requires no 
specific therapy. However, disseminated disease requires 
aggressive therapy that should be discussed with an ex-
pert. Danish strain BCG is resistant to current standard 
doses of isoniazid as well as to pyrazinamide and ethion-
amide.47 Induction of resistance in inappropriately treat-
ed cases with systemic disease has been documented.48
NON-TUBERCULOSIS MYCOBACTERIA
One study from Thailand reports on non-tuberculosis 
mycobacterial IRIS in children. Of 153 children initiating 
therapy at a median age of 7.9 years, 9 had IRIS caused 
by non-tuberculosis mycobacteria, 2 with paradoxical 
deterioration and 7 with unmasking disease. The rate 
was 5.9 cases per 100.5 There are no data for South Af-
rican children, although cases do occur (Helena Rabie 
- unpublished data).
IRIS INVOLVING SKIN CHANGES
Skin changes are the most common form of IRIS in adults, 
but there are fewer data in children. Unpublished data 
from KwaZulu-Natal reported by Boulware in a review 
on IRIS indicated that 53% of children had a new on-
set of rash after the initiation of HAART.1 These included 
molluscum contagiosum (8%), tinea capitis (20%), warts 
(16%), impetigo (12%), herpes zoster (5%), and other 
fungal rashes (24%).1 Earlier cohorts reported that 11% 
of children developed herpes zoster. Children at risk were 
negative for varicella antibody despite a previous history 
of varicella and had severe immunodeficiency before 
treatment.49 
Exacerbation of warts and molluscum contagiosum is 
commonly seen. If areas such as the face are involved, 
this disfigurement can be very disruptive and may lead 
to non-adherence. 
OTHER PHENOMENA
Cryptococcus neoformans is common in South African 
adults50 but less common in children. In children <15 
years of age, the incidence is 1 per 100 000 population.51 
C. neoformans IRIS of both the central nervous system 
and the lungs occurs occasionally.52
Guillain Barré syndrome, myocardial dilatation, exacer-
bation of JC virus progressive multifocal leucoencepha-
lopathy, leprosy, Kaposi’s sarcoma, cytomegalovirus, 
Pneumocystis pneumonia (PCP), opsoclonus-myoclonus 
syndrome, toxoplasmosis and other entities have been 
reported in adults and in children.3,41,53-55
CONCLUSION
IRIS is common in children. BCG is important in infants 
and TB is more prevalent in older children. Although the 
morbidity is thought to be low, IRIS may be diagnostically 
challenging and carry a high morbidity. A higher drug 
burden may result in decreased therapeutic success, 
with possible non-adherence and more potential for 
drug interactions as well. A careful history and clinical 
review remain important tools in the diagnosis and 
management of these conditions.
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